首页> 外国专利> OPTIMIZED LENTIVIRAL VECTOR FOR STEM CELL GENE THERAPY OF HEMOGLOBINOPATHIES

OPTIMIZED LENTIVIRAL VECTOR FOR STEM CELL GENE THERAPY OF HEMOGLOBINOPATHIES

机译:血红蛋白病干细胞基因治疗的优化慢病毒载体

摘要

In certain embodiments an optimized derivative of the CCLc-βAS3-FB lentiviral vector termed (CCLc-mGata/ANK-CoreLCR-βAS3-FB), is provided which is capable of driving lineage-restricted expression of a beta-globin gene (e.g., an anti-sickling β-globin like gene (βA83)). In certain embodiments the vectors described herein comprise novel defined LCR HS core sequences (HS2(˜420 bp), HS3β40 bp), HS4(˜410 bp)) which can be used to replace the putative LCR HS sequences present within the “mini-LCR” (˜3.6 kb reduced to ˜1.2 kb) to produce an “optimized mini-LCR”.
机译:在某些实施方案中,提供了被称为(CCLc-mGata /ANK-CoreLCR-βAS3-FB)的CCLc-βAS3-FB慢病毒载体的优化衍生物,其能够驱动β-珠蛋白基因的谱系限制表达(例如,抗镰状β球蛋白基因(βA83))。在某些实施方案中,本文描述的载体包含新颖的定义的LCR HS核心序列(HS2(〜420 bp),HS3β40bp),HS4(〜410 bp),其可用于替换“ mini- LCR”(从约3.6 kb减少到约1.2 kb)以产生“优化的mini-LCR”。

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号